Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages 1784-1792

  Reka, Ajaya Kumar ^a   Kuick, Rork ^b   Kurapati, Himabindu ^a   Standiford, Theodore J ^a   Omenn, Gilbert S ^c,d   Keshamouni, Venkateshwar G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c School of Public Health   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Connectivity map; Epithelial mesenchymal transition; HSP90; Lung cancer; mTOR; PI3K; TGF beta

Indexed keywords

17 DIETHYLAMINOGELDANAMYCIN; 2 MORPHOLINO 8 PHENYLCHROMONE; 4,5 DIANILINOPHTHALIMIDE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; ACETYLSALICYLIC ACID; CHLORPROMAZINE; CLOZAPINE; CYCLOSPORIN; DICLOFENAC; FASUDIL; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; LM 1685; MAMMALIAN TARGET OF RAPAMYCIN; MERCAPTOPURINE; NORDIHYDROGUAIARETIC ACID; NOVOBIOCIN; OXAPROZIN; PROTEIN INHIBITOR; RAPAMYCIN; SMAD PROTEIN; STAUROSPORINE; TANESPIMYCIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER GROWTH; CELL CULTURE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 80054932086     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822adfb0     Document Type: Article

References (54)

1. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003;3:362-374. (Pubitemid 37328856)
2. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-1428.
3. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6:506-520. (Pubitemid 43980540)
4. Kasai H, Allen JT, Mason RM, et al. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 2005;6:56.
5. Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002;109:1551-1559. (Pubitemid 34663517)
6. Davies M, Robinson M, Smith E, et al. Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J Cell Biochem 2005;95:918-931. (Pubitemid 41420140)
7. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003;4:657-665. (Pubitemid 36934968)
8. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-142. (Pubitemid 43278296)
9. Lee JM, Dedhar S, Kalluri R, et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006;172:973-981.
10. Gerhold DL, Jensen RV, Gullans SR. Better therapeutics through microarrays. Nat Genet 2002;32(Suppl):547-551.
11. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 2007;7:54-60. (Pubitemid 46020847)
12. Sartor MA, Mahavisno V, Keshamouni VG, et al. ConceptGen: a gene set enrichment and gene set relation mapping tool. Bioinformatics 2010;26:456-463.
13. Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-1935. (Pubitemid 44497995)
14. Zhang SD, Gant TW. A simple and robust method for connecting small-molecule drugs using gene-expression signatures. BMC Bioinformatics 2008;9:258.
15. Reka AK, Kurapati H, Narala VR, et al. Peroxisome proliferator activated receptor-activation inhibits tumor metastasis by antagonizing Smad3 mediated epithelial mesenchymal transition. Mol Cancer Ther 2010;9:3221-3232.
16. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000;1:169-178.
17. Rodina A, Vilenchik M, Moulick K, et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat Chem Biol 2007;3:498-507. (Pubitemid 47080368)
18. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002;2:3-24. (Pubitemid 34462457)
19. Papadimitrakopoulou V, Adjei AA. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. J Thorac Oncol 2006;1:749-751. (Pubitemid 47163973)
20. Workman P, Clarke PA, Raynaud FI, et al. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010;70:2146-2157.
21. Gridelli C, Maione P, Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 2008;13:139-147. (Pubitemid 351342577)
22. Donnelly A, Blagg BS. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem 2008;15: 2702-2717.
23. Burlison JA, Neckers L, Smith AB, et al. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J Am Chem Soc 2006;128:15529-15536. (Pubitemid 44876029)
24. Chen Q. Nordihydroguaiaretic acid analogues: their chemical synthesis and biological activities. Curr Top Med Chem 2009;9:1636-1659.
25. Krysan K, Reckamp KL, Sharma S, et al. The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem 2006; 6:209-220. (Pubitemid 43796639)
26. Swannie HC, Kaye SB. Protein kinase C inhibitors. Curr Oncol Rep 2002;4:37-46.
27. Lee MS, Johansen L, Zhang Y, et al. The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. Cancer Res 2007;67:11359-11367. (Pubitemid 350248563)
28. Williams CS, Sheng H, Brockman JA, et al. A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia 2001;3:428-436. (Pubitemid 32988813)
29. Winters ME, Mehta AI, Petricoin EF III, et al. Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis. Cancer Res 2005;65:3853-3860. (Pubitemid 40616366)
30. Fontaine E, McShane J, Page R, et al. Aspirin and non-small cell lung cancer resections: effect on long-term survival. Eur J Cardiothorac Surg 2010;38:21-26.
31. Liu Y, Zhang Y, Min J, et al. Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer. Tumour Biol 2010; 31:199-207.
32. Eckstein LA, Van Quill KR, Bui SK, et al. Cyclosporin A inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells. Invest Ophthalmol Vis Sci 2005;46: 782-790. (Pubitemid 41321012)
33. Zhu F, Zhang Z, Wu G, et al. Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549. Med Oncol.
34. Stork LC, Matloub Y, Broxson E, et al. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standardrisk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. Blood 2010;115:2740-2748.
35. Quann EJ, Khwaja F, Zavitz KH, et al. The aryl propionic acid Rflurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res 2007;67:3254-3262. (Pubitemid 46724863)
36. Dinney CP, Parker C, Dong Z, et al. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin Cancer Res 1997;3:161-168. (Pubitemid 27107290)
37. Haince JF, Rouleau M, Hendzel MJ, et al. Targeting poly(ADPribosyl) ation: a promising approach in cancer therapy. Trends Mol Med 2005;11:456-463. (Pubitemid 41415725)
38. Moon D-O, Kim M-O, Choi YH, et al. Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation. Mol Cancer Ther 2010;9:1583-1595.
39. Shin SY, Choi BH, Ko J, et al. Clozapine, a neuroleptic agent, inhibits Akt by counteracting Ca2-/calmodulin in PTEN-negative U-87MG human glioblastoma cells. Cell Signal 2006;18:1876-1886.
40. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-454.
41. Roberts AB, Tian F, Byfield SD, et al. Smad3 is key to TGF-betamediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 2006;17:19-27. (Pubitemid 43117513)
42. Reka AK, Kurapati H, Narala VR, et al. Peroxisome proliferatoractivated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther 2010;9:3221-3232.
43. Wrighton KH, Lin X, Feng XH. Critical regulation of TGFbeta signaling by Hsp90. Proc Natl Acad Sci USA 2008;105:9244-9249.
44. Vilar E, Mukherjee B, Kuick R, et al. Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKTmammalian target of rapamycin pathway. Clin Cancer Res 2009;15: 2829-2839.
45. De Preter K, De Brouwer S, Van Maerken T, et al. Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds. Clin Cancer Res 2009;15:3690-3696.
46. Hassan SB, Gali-Muhtasib H, Goransson H, et al. Alpha terpineol: a potential anticancer agent which acts through suppressing NF-kappaB signalling. Anticancer Res 2010;30:1911-1919.
47. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-484. (Pubitemid 43199434)
48. Ebi H, Tomida S, Takeuchi T, et al. Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. Cancer Res 2009;69:4027-4035.
49. Lamouille S, Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 2007;178:437-451. (Pubitemid 47196152)
50. Chen Y-G, Liu F, Massague J. Mechanism of TGF[beta] receptor inhibition by FKBP12. EMBO J 1997;16:3866-3876. (Pubitemid 27281003)
51. Huse M, Muir TW, Xu L, et al. The TGF beta receptor activation process: an inhibitor-to substrate-binding switch. Mol Cell 2001;8:671-682. (Pubitemid 32946943)
52. Wang T, Donahoe PK, Zervos AS. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. Science 1994;265:674-676. (Pubitemid 24268280)
53. Bakin AV, Tomlinson AK, Bhowmick NA, et al. Phosphatidylinositol 3-kinase function is required for transforming growth factor betamediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000;275:36803-36810. (Pubitemid 32002090)
54. Woolf PJ, Alvarez A, Keshamouni VG. Systems approach for understanding metastasis. In Keshamouni VG, Arenberg DA, Kalemkerian GP (Eds). Lung Cancer Metastasis: Novel Biological Mechanisms and Impact on clinical Practice. New York, NY: Springer, 2009. Pp. 383-394.